Combination Therapy with Platinum and Etoposide of Brain Metastases from Breast Carcinoma

References

• Posner J B. Management of central nervous system metastases. Sem Oncol 1977; 4: 81–91
   PubMed Web of Science ®Google Scholar
• Greig N H. Chemotherapy of brain metastases: current status. Cancer Treat Rev 1984; 11: 157–186
   PubMed Web of Science ®Google Scholar
• Sheline G E, Brady L W. Radiation therapy for brain metastases. J Neuro-oncol 1987; 4: 219–225
   PubMed Web of Science ®Google Scholar
• Gelber R, Larson M, Borgelt B, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 1981; 48: 1749–1753
   PubMed Web of Science ®Google Scholar
• Wilson C. Single agent chemotherapy of brain tumors, a five year review. Arch Neurol 1976; 33: 739–744
   PubMed Web of Science ®Google Scholar
• Kolaric K, Roth A, Jelicic I, et al. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) in metastatic brain tumors. J Cancer Res Clin Oncol 1982; 104: 287–293
   PubMed Web of Science ®Google Scholar
• Rosner D, Nemoto T, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–839
   PubMed Web of Science ®Google Scholar
• Cocconi G, Tonato M, Di Costanzo F, et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Eur J Cancer Clin Oncol 1986; 7: 761–764
   Google Scholar
• Bisagni G, Cocconi G, Buzzi F, et al. Platinum (P) and etoposide (E) as a third line chemotherapy regimen in advanced breast cancer (abc). A randomized trial of the Italian Oncology Group for Clinical Reserach (G.O.I.R.C.) (abstr). Cancer Chemother Pharmacol 1986; 23(suppl 1)A9
   Google Scholar
• EORTC Breast Cooperative Group. Revision of standards for the assessment of hormone receptors in human breast cancer: Report of the second EORTC workshop, held on 16–17 March, 1979, in The Netherlands Cancer Institute. Eur J Cancer 1980; 16: 1513–1515
   PubMed Web of Science ®Google Scholar
• Passalacqua R, Bozzetti C, Bisagni G, et al. Prognostic role of estrogen receptor in primary breast carcinoma using a new method for selecting cut-off value (abstr). Cancer Chemother Pharmacol 1986; 18(suppl 1)55A
   Google Scholar
• Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radial Oncol Biol Phys 1980; 6: 1–9
   Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Halperin M, Blackwelder W C. Verier 31: Estimation of the multivariate logistic risk function: A comparison of the discriminant function and maximum likelihood approaches. J Chron Dis 1980; 24: 125–158
   Google Scholar
• Cox D R. Regression models of life tables (with discussion). J Roy Statist Soc B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Lee Y N. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983; 23: 175–180
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fouad A, Pickren J W, et al. Central nervous system metaslasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349–2354
   PubMed Web of Science ®Google Scholar
• Bunting J S, Hemsted E H, Kremer J K. The pattern of spread and survival in 596 cases of breast cancer related to clinical staging and histological grade. Clin Radiol 1976; 27: 9–15
   PubMed Web of Science ®Google Scholar
• Paterson A HG, Agarwal M, Lee A, et al. Brain metaslases in breasl cancer patients receiving adjuvant chemotherapy. Cancer 1982; 49: 651–654
   PubMed Web of Science ®Google Scholar
• Canellos G P, Gold G L, Schein P S, et al. Combination chemotherapy for advanced breast cancer; response and effect on survival. Ann Intern Med 1976; 84: 389–392
   PubMed Web of Science ®Google Scholar
• Greenspan E M, Fieber M, Lesnick G, et al. Response of advanced breast cancer to combination of antimetabolite, methotrexate and the alkylating agent, thiotepa. J Mount Sinai Hosp 1963; 30: 246–267
   PubMedGoogle Scholar
• Cocconi G, Bisagni G, De Lisi V, et al. Platinum and etoposide as a first-line chemotherapy for metastatic breast carcinoma. Preliminary results of a prospective randomized trial (abstr). Proc Am Soc Clin Oncol 1988; 7: 13
   Google Scholar
• Fewer D. Phase II study of l-2-(chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors. Cancer Chemother Rep 1972; 56: 421–427
   PubMedGoogle Scholar
• Pouillard P, Mathé G, Thy T H, et al. Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trial. Cancer 1976; 38: 1909–1916
   PubMed Web of Science ®Google Scholar
• Di Benedetto G, Percia C, Puppo F, et al. Chemioterapia dei tumori cerebrali metastatici; valutazione dell efficacia terapeutica e degli effetti collaterali. Atti Accad Med Lomb 1980; 33: 113
   Google Scholar
• Paolelti P, Rubustelli Delia Cuna G, Knerich R, et al. Multidisciplinary treatment for central nervous system lumors with nitrosourea compounds. Acta Neurochir (Wien) 1978; 41: 287
   PubMed Web of Science ®Google Scholar
• Ruggiero G, Finizio F S, Manfredini M, et al. CT evaluation of radiochemotherapy in the treatment of cerebral metastases. J Neuroradiol 1983; 10: 275–280
   PubMed Web of Science ®Google Scholar
• Stewart D J, Feun L G, Maor M, et al. Weekly cisplatin during cranial irradiation for malignant melanoma metastatic to the brain. J Neuro-oncol 1983; 1: 49–51
   PubMedGoogle Scholar
• Madajewicz S, West C R, Avellanosa A M, et al. Phase II study of intra-arterial (ia) cis-platinum (DDP) therapy of metastatic brain tumors. Proc UICC Conference on Clinical Oncology, Lausanne, 1981, (abstr)
   Google Scholar
• Cascino T L, Byrne T N, Deck M DF, et al. Intra-arterial BCNU in the treatment of metastatic brain tumors. J Neuro-oncol 1983; 1: 211–218
   PubMedGoogle Scholar
• Feun L M, Wallace S, Stewart D J, et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984; 54: 794–799
   PubMed Web of Science ®Google Scholar
• Neuwelt E A, Dahlborg S A. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neuro-oncol 1987; 4: 195–207
   PubMed Web of Science ®Google Scholar
• Durand R F, Goldie J H. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673–679
   PubMedGoogle Scholar
• Schabel F, Trader M W, Laster W K, et al. Cis-dichlorodammine-platinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459–1473
   PubMedGoogle Scholar
• Stewart D J, Leavens M, Friedman J, et al. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Res 1980; 40: 3163–3166
   PubMed Web of Science ®Google Scholar
• Stewart D J, Benvenuto J, Leavens M, et al. Central nervous system clinical pharmacology of pentamethylmelamine. J Neuro-oncol 1983; 1: 357–364
   PubMedGoogle Scholar
• Stewart D J, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982; 42: 2474–2479
   PubMed Web of Science ®Google Scholar
• Stewart D J, Benjamin R S, Luna M, et al. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 1982; 10: 51–54
   PubMed Web of Science ®Google Scholar
• Stewart D J, Richard M T, Hugenholtz H, et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-oncol 1984; 2: 133–139
   PubMed Web of Science ®Google Scholar